Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.38 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | SPR | P35270 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17936828 | 1.00 | MAP4K4 (0.39) | MAP4K4GPR119SETD7NR1H2MEN1 | |
| SCHEMBL17936822 | 1.00 | MAP4K4 (0.39) | MAP4K4GPR119SETD7NR1H2MEN1 | |
| SCHEMBL28883948 | 0.84 | NR1H2 (0.39) | GPR119NR1H2MEN1KMT2AHSD11B1 | |
| SCHEMBL31451499 | 0.84 | MEN1 (0.41) | NR1H2MEN1KMT2AHSD11B1USP30 | |
| SCHEMBL19860150 | 0.81 | SCN9A (0.34) | MAP4K4GPR119SETD7NR1H2HDAC1 | |
| SCHEMBL28556462 | 0.80 | GRM5 (0.35) | — | |
| SCHEMBL17925873 | 0.79 | GRM5 (0.33) | — | |
| SCHEMBL19784976 | 0.79 | GPR119 (0.38) | MAP4K4GPR119SETD7NR1H2MEN1 | |
| SCHEMBL19781282 | 0.77 | MEN1 (0.37) | MAP4K4GPR119NR1H2MEN1KMT2A | |
| SCHEMBL19781607 | 0.77 | MEN1 (0.37) | MAP4K4GPR119NR1H2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118946555-A | Compounds having T-structures formed by at least four rings for use in the treatment of cancer and other indications | 瑟拉斯有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-115806561-A | JAK3 selective inhibitors and uses thereof | 南京药石科技股份有限公司 | 2023-03-17 | — | — | CN | disclosed |
| CN-109476668-B | 6, 7-dihydro-4H-pyrazolo [1,5-a ] pyrazines and 6, 7-dihydro-4H-triazolo [1,5-a ] pyrazines for the treatment of infectious diseases | 豪夫迈·罗氏有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-11168086-B2 | Methods of synthesizing pyrazine compounds | HOFFMANN-LA ROCHE INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-11168086-B2 | Methods of synthesizing pyrazine compounds | HOFFMANN-LA ROCHE INC. (US) | 2021-11-09 | — | — | US | disclosed |
| EP-3458455-B1 | NOVEL PYRAZINE COMPOUNDS WITH OXYGEN, SULFUR AND NITROGEN LINKER FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | disclosed |
| EP-3458455-B1 | NOVEL PYRAZINE COMPOUNDS WITH OXYGEN, SULFUR AND NITROGEN LINKER FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | disclosed |
| CN-109153682-B | Novel pyrazine compounds with oxygen, sulfur and nitrogen linkers for the treatment of infectious diseases | 豪夫迈·罗氏有限公司 | 2021-05-25 | — | — | CN | disclosed |
| CN-109415368-B | Carboxy 6, 7-dihydro-4H-pyrazolo [1,5-a ] pyrazine compounds for the treatment of infectious diseases | 豪夫迈·罗氏有限公司 | 2021-04-30 | — | — | CN | disclosed |
| US-10683299-B2 | Pyrazolopyrazine and triazolopyrazine compounds for the treatment of infectious diseases | HOFFMANN LA ROCHE INC. (US) | 2020-06-16 | — | — | US | disclosed |
| WO-2018011160-A1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-18 | — | — | WO | disclosed |
| WO-2018011163-A1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE AND 6,7-DIHYDRO-4H-TRIAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-18 | — | — | WO | disclosed |
| WO-2018011162-A1 | CARBOXY 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-18 | — | — | WO | disclosed |
| WO-2017198744-A1 | NOVEL PYRAZINE COMPOUNDS WITH OXYGEN, SULFUR AND NITROGEN LINKER FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017198744-A1 | NOVEL PYRAZINE COMPOUNDS WITH OXYGEN, SULFUR AND NITROGEN LINKER FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-23 | — | — | WO | disclosed |
| EP-3245206-A1 | PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. Hoffmann-La Roche AG (CH) | 2017-11-22 | — | — | EP | disclosed |
| US-20160237090-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160237090-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2016113273-A1 | PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-07-21 | — | — | WO | disclosed |
| WO-2016113273-A1 | PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168086-B2 | Methods of synthesizing pyrazine compounds | CYP3A5, HAVCR2, HCCS | MAP4K4 2727/4885GPR119 1377/4885SETD7 2774/4885 |
| US-20160237090-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HAVCR2, NR1H4, ZC3HAV1 | MAP4K4 2670/4885GPR119 269/4885SETD7 3820/4885 |
| US-10683299-B2 | Pyrazolopyrazine and triazolopyrazine compounds for the treatment of infectious diseases | CYP3A5, RRP15, QDPR | MAP4K4 878/4885GPR119 1086/4885SETD7 3577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.